Article Text

Download PDFPDF
Autoantibodies to C-Reactive Protein in Incomplete Lupus and Systemic Lupus Erythematosus
  1. Ju-Yang Jung, MD,
  2. Bo-Ram Koh, MD,
  3. Hyoun-Ah Kim, MD,
  4. Ja-Young Jeon, PhD,
  5. Chang-Hee Suh, MD, PhD
  1. From the Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
  1. Received January 5, 2014, and in revised form April 9, 2014.
  2. Accepted for publication April 17, 2014.
  3. Drs. Jung and Koh contributed equally.
  4. Reprints: Chang-Hee Suh, MD, PhD, Department of Rheumatology, Ajou University School of Medicine, San 5, Wonchon-dong, Yeongtong-gu, Suwon, Korea 443-721. E-mail: chsuh{at}


Objective Anti-C-reactive protein (CRP) antibodies have been described in patients with systemic lupus erythematosus (SLE). We investigated the potential of the anti-CRP antibody as a marker for disease activity in SLE patients and as a predictor of progression to SLE in patients with incomplete lupus.

Methods Immunoglobulin G anti-CRP antibody levels were measured using an enzyme-linked immunosorbent assay.

Results Patients with incomplete lupus exhibited clinical and immunologic characteristics different from those in SLE patients: no serositis and alopecia, more common oral ulcers and arthritis, lower disease activity index, lower positivity for antinuclear and anti–double-strand DNA antibodies, and higher complement levels. Anti-CRP antibody levels were higher in SLE patients (35.6 [35.1] AU) than in patients with incomplete lupus (23.1 [25.8] AU, P = 0.016) and normal controls (21.0 [14.3] AU, P < 0.001). Anti-CRP antibody was significantly higher in SLE patients with arthritis and correlated with disease activity markers, including antichromatin antibody. However, no difference in anti-CRP antibody levels was observed between patients with incomplete lupus that progressed to SLE and those whose did not.

Conclusion These data suggest that anti-CRP antibodies can neither be used as biomarkers in SLE nor predict SLE progression in patients with incomplete lupus.

Key Words
  • autoantibody
  • biomarker
  • C-reactive protein
  • disease activity
  • lupus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.